This is the authors' abstract. We don't add key points for this paper.
// Alessio Montresor 1, 2 , Lara Toffali 1, 2 , Michela Mirenda 1 , Antonella Rigo 3 , Fabrizio Vinante 3 , Carlo Laudanna 1, 2 1 Department of Pathology and Diagnostics, Division of General Pathology, Laboratory of Cell Trafficking and Signal Transduction, University of Verona, Verona 37134, Italy, EU 2 The Center for Biomedical Computing (CBMC), University of Verona, Verona 37134, Italy, EU 3 Department of Medicine, Section of Hematology, Cancer Research & Cell Biology Laboratory, University of Verona, Verona 37134, Italy, EU Correspondence to: Carlo Laudanna, e-mail: carlo.laudanna@univr.it Keywords: chronic lymphocytic leukemia, adhesion, integrin activation, chemokines, JAKs Received: May 21, 2015 Accepted: August 28, 2015 Published: September 10, 2015 ABSTRACT Chemokines participate to B-cell chronic lymphocytic leukemia (B-CLL) pathogenesis by promoting cell adhesion and survival in bone marrow stromal niches and mediating cell dissemination to secondary lymphoid organs. In this study we investigated the role of JAK protein tyrosine kinases (PTK) in adhesion triggering by the CXC chemokine CXCL12 in normal versus CLL B-lymphocytes. We demonstrate that CXCL12 activates JAK2 in normal as well as CLL B-lymphocytes, with kinetics consistent with rapid adhesion triggering. By using complementary methodologies of signal transduction interference, we found that JAK2 mediates CXCL12-triggered activation of lymphocyte function-associated antigen-1 (LFA-1) and very late antigen-4 (VLA-4) integrins. We also show that JAK2 mediates the activation of the small GTP-binding protein RhoA, in turn controlling LFA-1 affinity triggering by CXCL12. Importantly, comparative analysis of 41 B-CLL patients did not evidence JAK2 functional variability between subjects, thus suggesting that JAK2, differently from other signaling events involved in adhesion regulation in B-CLL, is a signaling molecule downstream to CXCR4 characterized by a conserved regulatory role. Our results reveal JAK2 as critical component of chemokine signaling in CLL B-lymphocytes and indicate JAK inhibition as a potentially useful new pharmacological approach to B-CLL treatment.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Montresor et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: